



# **Supplemental Material**

**Figure S1. Forest plot of studies comparing all-cause mortality in Implantable Cardioverter Defibrillator (ICD) patients with atrial fibrillation (AF) and normal sinus rhythm (NSR). A Fixed-Effects model.**




Forest plot showing increased risk of mortality in ICD patients with AF compared to ICD patients in NSR

Figure S2. Funnel plot for all-cause mortality.




There appears to be paucity of studies published to the left of the final odds ratio of this meta-analysis, indicating a significant publication bias among studies comparing all-cause mortality between Implantable Cardioverter Defibrillator (ICD) patients with and without atrial fibrillation (AF)

Figure S3. Forest plot of studies with a priori hypothesis, comparing all-cause mortality in Implantable Cardioverter Defibrillator (ICD) patients with atrial fibrillation (AF) and normal sinus rhythm (NSR).




**Figure S4. Forest plot of studies with a priori hypothesis, comparing all-cause mortality in Implantable Cardioverter Defibrillator (ICD) patients with atrial fibrillation (AF) and normal sinus rhythm (NSR). A Fixed-Effects model.**




**Forest plot showing increased risk of mortality in ICD patients with AF compared to ICD patients in NSR**

**Figure S5. Forest Plot comparing mortality in AF patients with Implantable Cardioverter Defibrillator (ICD) vs goal directed medical therapy (GDMT). A Fixed-Effects model.**




**Forest plot showing increased risk of mortality in ICD patients with AF compared to ICD patients in NSR**

**Figure S6. Forest Plot comparing appropriate shock therapy in Implantable Cardioverter Defibrillator (ICD) patients with atrial fibrillation (AF) and normal sinus rhythm (NSR). A Fixed-Effects model.**



Forest plot showing no mortality benefit from ICD compared to medical therapy in AF patients

**Figure S7. Funnel plot for appropriate shock therapy.**



Forest plot showing increased risk of appropriate shocks in ICD patients with AF compared to ICD patients in NSR

The published studies are equally distributed on both sides of the final Odds Ratio of this meta-analysis, indicating no publication bias among studies comparing risk of appropriate shock therapy in Implantable Cardioverter Defibrillator (ICD) patients with and without atrial fibrillation (AF)



## Supplemental References:

1. Zareba W, Steinberg JS, McNitt S, Daubert JP, Piotrowicz K, Moss AJ. Implantable cardioverter-defibrillator therapy and risk of congestive heart failure or death in MADIT II patients with atrial fibrillation. *Heart Rhythm*. 2006;3:631–637.
2. Ryan S, Siemon G, Drogemuller A, Rameken M. 2 year follow-up of 321 patients with an implantable cardioverter/defibrillator: comparison of patients with and without atrial fibrillation. *z kardiol*. 2001;90:906–915.
3. Kraaier K, Van Rennes B, Oude Velthuis B, Dorman HGR, Stevenhagen YJ, Van Opstal J, Scholten MF. Impact of atrial fibrillation in an implantable cardioverter defibrillator cohort. *European Heart Journal*. 2013;34:P1408–P1408.
4. van Rees JB, Borleffs CJW, de Bie MK, Stijnen T, van Erven L, Bax JJ, Schalij MJ. Inappropriate Implantable Cardioverter-Defibrillator Shocks: Incidence, Predictors, and Impact on Mortality. *JAC*. 2011;57:556–562.
5. van Gelder IC, PHAN HM, Wilkoff BL, Brown ML, ROGERS T, PETERSON BJ, Birgersdotter-Green UM. Prognostic Significance of Atrial Arrhythmias in a Primary Prevention ICD Population. *Pacing and Clinical Electrophysiology*. 2011;34:1070–1079.
6. Borleffs CJW, Ypenburg C, van Bommel RJ, Delgado V, van Erven L, Schalij MJ, Bax JJ. Clinical importance of new-onset atrial fibrillation after cardiac resynchronization therapy. *HRTM*. 2009;6:305–310.
7. Bunch TJ, Day JD, Olshansky B, Stolen KQ, Mullin CM. Newly detected atrial fibrillation in patients with an implantable cardioverter-defibrillator is a strong risk marker of increased mortality. *HRTM*. 2009;6:2–8.
8. Köbe J, Wasmer K, Andresen D, Kleemann T, Spitzer SG, Jehle J, Brachmann J, Stellbrink C, Hochadel M, Senges J, Klein HU, Eckardt L. Impact of atrial fibrillation on early complications and one year-survival after cardioverter defibrillator implantation: Results from the German DEVICE registry. *International Journal of Cardiology*. 2013;168:4184–4190.
9. Smit MD, Van Dessel PFHM, Rienstra M, Nieuwland W, Wiesfeld ACP, Tan ES, Anthonio RL, Van Veldhuisen DJ, van Gelder IC. Atrial fibrillation predicts appropriate shocks in primary prevention implantable cardioverter-defibrillator patients. *Europace*. 2006;8:566–572.
10. Deneke T, Lawo T, Gerritse B, Lemke B. Mortality of patients with implanted cardioverter/defibrillators in relation to episodes of atrial fibrillation. *Europace*. 2004;6:151–158.
11. Madhavan M, Waks JW, Friedman PA, Kramer DB, Buxton AE, Noseworthy PA, Mehta RA, Hodge DO, Higgins AY, Webster TL, Witt CM, Cha Y-M, Gersh BJ. Outcomes After Implantable Cardioverter-Defibrillator Generator Replacement for Primary Prevention of Sudden Cardiac Death. *Circulation: Arrhythmia and Electrophysiology*. 2016;9:e003283.
12. Singh SN, Poole J, Anderson J, Hellkamp AS, Karasik P, Mark DB, Lee KL, Bardy GH. Role of amiodarone or implantable cardioverter/defibrillator in patients with atrial fibrillation and heart failure. *American Heart Journal*. 2006;152:974.e7–974.e11.
13. Grönefeld GC, Mauss O, Li Y-G, Klingenheben T, Hohnloser SH. Association between atrial fibrillation and appropriate implantable cardioverter defibrillator therapy: results from a prospective study. *Journal of Cardiovascular Electrophysiology*. 2000;11:1208–1214.
14. Kraaier K, Scholten MF, Tijssen JGP, Theuns DAMJ, Jordaens LJLM, Wilde AAM, van Dessel PFHM. Early mortality in prophylactic implantable cardioverter-defibrillator recipients: development and validation of a clinical risk score. *Europace*. 2013;16:40–46.
15. Marijon E, Trinquart L, Otmani A, Leclercq C, Fauchier L, Chevalier P, Klug D, Defaye

- P, Lellouche N, Mansourati J, Deharo J-C, Sadoul N, Anselme F, Maury P, Davy J-M. Predictors for short-term progressive heart failure death in New York Heart Association II patients implanted with a cardioverter defibrillator—the EVADEF study. *American Heart Journal*. 2010;159:659–664.e1.
16. Scherthaner C, Pichler M, Strohmer B. Lower body mass index and atrial fibrillation as independent predictors for mortality in patients with implantable cardioverter defibrillator. *Croatian medical journal*. 2007;48:59–67.
  17. Desai H, Aronow WS, Ahn C, Gandhi K, Hussain S, Lai HM, Sharma M, Frishman WH, Cohen M, Sorbera C. Risk factors for appropriate cardioverter-defibrillator shocks, inappropriate cardioverter-defibrillator shocks, and time to mortality in 549 patients with heart failure. *The American Journal of Cardiology*. 2010;105:1336–1338.
  18. Schefer T, Wolber T, Binggeli C, Holzmeister J, Brunckhorst C, Duru F. Long-term predictors of mortality in ICD patients with non-ischaemic cardiac disease: impact of renal function. *Europace*. 2008;10:1052–1059.
  19. Yang JH, Byeon K, Yim HR, Park JW, Park S-J, Huh J, Kim JS, On YK. Predictors and Clinical Impact of Inappropriate Implantable Cardioverter-Defibrillator Shocks in Korean Patients. *Journal of Korean Medical Science*. 2012;27:619–624.
  20. Stein KM, Mittal S, Gilliam FR, Gilligan DM, Zhong Q, Kraus SM, Meyer TE. Predictors of early mortality in implantable cardioverter-defibrillator recipients. *Europace*. 2009;11:734–740.
  21. Smith T, Theuns DAMJ, Caliskan K, Jordaens L. Long-Term Follow-Up of Prophylactic Implantable Cardioverter-Defibrillator-Only Therapy: Comparison of Ischemic and Nonischemic Heart Disease. *Clinical Cardiology*. 2011;34:761–767.
  22. Hess PL, Hellkamp AS, Peterson ED, Sanders GD, Al-Khalidi HR, Curtis LH, Hammill BG, Pun PH, Curtis JP, Anstrom KJ, Hammill SC, Al-Khatib SM. Survival After Primary Prevention Implantable Cardioverter-Defibrillator Placement Among Patients With Chronic Kidney Disease. *Circulation: Arrhythmia and Electrophysiology*. 2014;7:793–799.
  23. Kadish A, Dyer A, Daubert JP, Quigg R, Estes NAM, Anderson KP, Calkins H, Hoch D, Goldberger J, Shalaby A, Sanders WE, Schaechter A, Levine JH, Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. *The New England journal of medicine*. 2004;350:2151–2158.
  24. Rienstra M, Smit MD, Nieuwland W, Tan ES, Wiesfeld ACP, Anthonio RL, Van den Berg MP, Van Veldhuisen DJ, van Gelder IC. Persistent atrial fibrillation is associated with appropriate shocks and heart failure in patients with left ventricular dysfunction treated with an implantable cardioverter defibrillator. *American Heart Journal*. 2007;153:120–126.
  25. Caputo ML, Regoli F, Conte G, Adjibodou B, Svab S, Del Bufalo A, Moccetti T, Curti M, Klersy C, Auricchio A. Temporal trends and long term follow-up of implantable cardioverter defibrillator therapy for secondary prevention: A 15-year single-centre experience. *International Journal of Cardiology*. 2017;228:31–36.